Repare Therapeutics Inc. has completed its previously announced acquisition by XenoTherapeutics, Inc. and Xeno Acquisition Corp. All outstanding common shares of Repare have been acquired, with shareholders receiving approximately US$2.20 per share in cash and one non-transferable contingent value right $(CVR)$ for each share. The CVR entitles holders to potential future payments, subject to the terms of the contingent value rights agreement. Following the transaction, Repare’s common shares are expected to cease trading on the Nasdaq Global Select Market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repare Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-027394), on January 28, 2026, and is solely responsible for the information contained therein.
